New CAR-T therapy targets Tough-to-Treat blood cancers
NCT ID NCT06680752
Summary
This early-stage trial is testing a new CAR-T cell therapy called ARD103 for patients with acute myeloid leukemia or myelodysplastic syndrome that has returned or hasn't responded to previous treatments. The study aims to find the safest and most effective dose while checking if the therapy can help control these blood cancers. Researchers are enrolling 49 participants at multiple medical centers to evaluate both safety and initial signs of effectiveness.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA REFRACTORY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Novant Health Cancer Institute
RECRUITINGCharlotte, North Carolina, 28204, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Novant Health Cancer Institute
RECRUITINGWinston-Salem, North Carolina, 27201, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.